Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases.

Division of Clinical Virology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.
Molecular Pharmacology (Impact Factor: 4.12). 06/2001; 59(5):1181-6.
Source: PubMed

ABSTRACT Uridine-cytidine kinases (UCK) have important roles for the phosphorylation of nucleoside analogs that are being investigated for possible use in chemotherapy of cancer. We have cloned the cDNA of two human UCKs. The approximately 30-kDa proteins, named UCK1 and UCK2, were expressed in Escherichia coli and shown to catalyze the phosphorylation of Urd and Cyd. The enzymes did not phosphorylate deoxyribonucleosides or purine ribonucleosides. UCK1 mRNA was detected as two isoforms of approximately 1.8 and approximately 2.7 kb. The 2.7-kb band was ubiquitously expressed in the investigated tissues. The band of approximately 1.8 kb was present in skeletal muscle, heart, liver, and kidney. The two isoforms of UCK2 mRNA of 1.2 and 2.0 kb were only detected in placenta among the investigated tissues. The genes encoding UCK1 and UCK2 were mapped to chromosome 9q34.2-9q34.3 and 1q22-1q23.2, respectively. We tested 28 cytidine and uridine nucleoside analogs as possible substrates of the enzymes. The enzymes phosphorylated several of the analogs, such as 6-azauridine, 5-fluorouridine, 4-thiouridine, 5-bromouridine, N(4)-acetylcytidine, N(4)-benzoylcytidine, 5-fluorocytidine, 2-thiocytidine, 5-methylcytidine, and N(4)-anisoylcytidine. The cloning and recombinant expression of the two human UCKs will be important for development of novel pyrimidine ribonucleoside analogs and the characterization of their pharmacological activation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Uridine-cytidine kinase (UCK) catalyzes the phosphorylation of uridine and cytidine and activates pharmacological ribonucleoside analogs. Here we present the crystal structures of human UCK alone and in complexes with a substrate, cytidine, a feedback inhibitor, CTP or UTP, and with phosphorylation products, CMP and ADP, respectively. Free UCK takes an α/β mononucleotide binding fold and exists as a homotetramer with 222 symmetry. Upon inhibitor binding, one loop region was loosened, causing the UCK tetramer to be distorted. Upon cytidine binding, a large induced fit was observed at the uridine/cytidine binding site, which endows UCK with a strict specificity for pyrimidine ribonucleosides. The first UCK structure provided the structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase, which give clues for the design of novel antitumor and antiviral ribonucleoside analogs that inhibit RNA synthesis.
    Structure 05/2004; 12(5):751-764. DOI:10.1016/S0969-2126(04)00121-2 · 6.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract DNA methylation and histone modification are epigenetic mechanisms that result in altered gene expression and cellular phenotype. The exact role of methylation in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) remains unclear. However, aberrations (e.g. loss-/gain-of-function or up-/down-regulation) in components of epigenetic transcriptional regulation in general, and of the methylation machinery in particular, have been implicated in the pathogenesis of these diseases. In addition, many of these components have been identified as therapeutic targets for patients with MDS/AML, and are also being assessed as potential biomarkers of response or resistance to hypomethylating agents (HMAs). The HMAs 5-azacitidine (AZA) and 2'-deoxy-5-azacitidine (decitabine, DAC) inhibit DNA methylation and have shown significant clinical benefits in patients with myeloid malignancies. Despite being viewed as mechanistically similar drugs, AZA and DAC have differing mechanisms of action. DAC is incorporated 100% into DNA, whereas AZA is incorporated into RNA (80-90%) as well as DNA (10-20%). As such, both drugs inhibit DNA methyltransferases (DNMTs; dependently or independently of DNA replication) resulting in the re-expression of tumor-suppressor genes; however, AZA also has an impact on mRNA and protein metabolism via its inhibition of ribonucleotide reductase, resulting in apoptosis. Herein, we first give an overview of transcriptional regulation, including DNA methylation, post-translational histone-tail modifications, the role of micro-RNA and long-range epigenetic gene silencing. We place special emphasis on epigenetic transcriptional regulation and discuss the implication of various components in the pathogenesis of MDS/AML, their potential as therapeutic targets, and their therapeutic modulation by HMAs and other substances (if known). The main focus of this review is laid on dissecting the rapidly evolving knowledge of AZA and DAC with a special focus on their differing mechanisms of action, and the effect of HMAs on transcriptional regulation.
    Drug Metabolism Reviews 01/2015; DOI:10.3109/03602532.2014.995379 · 6.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Uridine 5'-monophosphate (5'-UMP) and cytidine 5'-monophosphate (5'-CMP) were biosynthesized by recombinant uridine-cytidine kinase (UCK) and acetate kinase (ACK). The ack and uck genes from Escherichia coli K12 and the uck1, uck2 and ack genes from Lactobacillus bulgaricus ATCC 11842 were cloned and inserted into the plasmid pET-28a. All of the recombinant E. coli strains were capable of overexpressing UCK and ACK, which catalyzed the reaction using guanosine 5'-triphosphate (GTP) as a phosphate intermediate that was regenerated by ACK from acetyl phosphate. The effect of several parameters, including the substrate concentration, the GTP concentration, the temperature and the reaction pH, were optimized. High efficiency was achieved if uridine or cytidine was phosphorylated by UCK encoded by uck from E. coli and ACK encoded by ack from L. bulgaricus. The maximum conversion yield of 5'-UMP and 5'-CMP was 97% at 37°C and pH 7.5 when 30mM uridine/cytidine and 0.5mM GTP in a total of 1mL were used. In addition, the 5'-UMP and 5'-CMP products were very stable in the reaction system and did not undergo significant degradation.
    Journal of Biotechnology 08/2014; 188. DOI:10.1016/j.jbiotec.2014.08.018 · 2.88 Impact Factor